Design and synthesis of 3′,5′-ansa-adenosines as potential Hsp90 inhibitors

Tetrahedron Letters

Volumn 50, Issue 36, 2009, Pages 5102-5106

  Muranaka, Kazuhiro ^a   Ichikawa, Satoshi ^a   Matsuda, Akira ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; BENZYL DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; NATURAL PRODUCT;

ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG SYNTHESIS; HYDROGEN BOND; QUANTUM YIELD; REACTION ANALYSIS; RING CLOSING METATHESIS;

EID: 67650489791     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2009.06.094     Document Type: Article

References (50)

1. Bukau B., Deuerling E., Pfund C., and Craig E.A. Cell 101 (2000) 119-122
2. Hartl F.U., and Hayer-Hartl M. Science 295 (2002) 1852-1858
3. Young J.C., Agashe V.R., Siegers K., and Hartl F.U. Nat. Rev. Mol. Cell Biol. 5 (2004) 781-791
4. Smith D.F., Whitesell L., and Katsanis E. Pharm. Rev. 50 (1998) 493-514. http://www.picard.ch/downloads/Hsp90interactors.pdf The updated list is available at
5. Pratt W.B. Proc. Soc. Exp. Biol. Med. 217 (1998) 420-434
6. Xu W., and Neckers L. Clin. Cancer Res. 13 (2007) 1625-1629
7. Deboer C., Meulman P.A., Wnuk R.J., and Peterson D.H. J. Antibiot. 23 (1970) 442-447
8. Rinehart Jr. K.L., Sasaki K., Slomp G., Grostic M.F., and Olson E.C. J. Am. Chem. Soc. 92 (1970) 7591-7593
9. Whitesell L., Shifrin S.D., Schwab G., and Neckers L.M. Cancer Res. 52 (1992) 1721-1728
10. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., and Neckers L.M. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8324-8328
11. Schnur R.C., Corman M.L., Gallaschun R.J., Cooper B.A., Dee M.F., Doty J.L., Muzzi M.L., Moyer J.D., DiOrio C.I., Barbacci E.G., Miller P.E., O'Brien A.T., Morin M.J., Foster B.A., Pollack V.A., Savage D.M., Sloan D.E., Pustilnik L.R., and Moyer M.P. J. Med. Chem. 38 (1995) 3806-3812
12. Schulte T.W., and Neckers L.M. Cancer Chemother. Pharmacol. 42 (1998) 273-279
13. Banerji U. Proc. Am. Assoc. Cancer Res. 44 (2003) 677
14. Sausville E.A. Curr. Cancer Drug Target 3 (2003) 377-383
15. Tian Z.-Q., Liu Y., Zhang D., Wang Z., Dong S.D., Carreras C.W., Zhou Y., Rastelli G., Santi D.V., and Myles D.C. Bioorg. Med. Chem. 12 (2004) 5317-5329
16. Jez J.M., Chen J.C.-H., Rastelli G., Stroud R.M., and Santi D.V. Chem. Biol. 10 (2003) 361-368
17. Qin H.-L., and Panek J.S. Org. Lett. 10 (2008) 2477-2479
18. Andrus M.B., Meredith E.L., Hicken E.J., Simmons B.L., Glancey R.R., and Ma W. J. Org. Chem. 68 (2003) 8162-8169
19. Andrus M.B., Meredith E.L., Simmons B.L., Soma S.B.B.V., and Hicken E.J. Org. Lett. 4 (2002) 3549-3552
20. Grenert J.P., Sullivan W.P., Fadden P., Haystead T.A., Clark J., Mimnaugh E., Krutzsch H., Ochel H.J., Schulte T.W., Sausville E., Neckers L.M., and Toft D.O. J. Biol. Chem. 272 (1997) 23843-23850
21. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., and Pavletich N.P. Cell 89 (1997) 239-250
22. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Cell 90 (1997) 65-75
23. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., and Neckers L.M. Cell Stress Chaperones 3 (1998) 100-108
24. Sharma S.V., Agatsuma T., and Nakano H. Oncogene 16 (1998) 2639-2645
25. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. J. Med. Chem. 42 (1999) 260-266
26. Lee Y.-S., Mercu M.G., and Neckers L. Chem. Biol. 11 (2004) 991-998
27. Bergerat A., Massy B., Gadelle D., Varoutas P.-C., Nicolas A., and Forterre P. Nature 386 (1997) 414-417
28. Dutta R., and Inouye M. Trends Biochem. Sci. 25 (2000) 24-28
29. Clevenger R.C., and Blagg B.S.J. Org. Lett. 6 (2004) 4459-4462
30. Shen G., and Blagg B.S.J. Org. Lett. 7 (2005) 2157-2160
31. Shen G., Wang M., Welch T.R., and Blagg B.S.J. J. Org. Chem. 71 (2006) 7618-7631
32. Initially, the assembly by a simple amide formation between an α,β-unsaturated carboxylic acid derivative of adenosine moiety and the aniline 8 was attempted to prepare the precursor 15. However, these efforts were failed to occur, and only a trace amount of 15 was obtained presumably because of the low reactivity of either the carboxylic acid derivative or 8.
33. Andrus M.B., Hicken E.J., Meredith E.L., Simmons B.L., and Cannon J.F. Org. Lett. 5 (2003) 3859-3862
34. Prakash T.P., Kawasaki A.M., Fraser A.S., Vasquez G., and Manoharan M. J. Org. Chem. 67 (2002) 357-369
35. Wagner D., Verheyden J.P.H., and Moffatt J.G. J. Org. Chem. 39 (1974) 24-30
36. Schauer D.J., and Helquist P. Synthesis 21 (2006) 3654-3660
37. Recent reviews:. Schmidt B. Eur. J. Org. Chem. (2004) 1865-1880
38. Hoveyda A.H., Gillingham D.G., Van Veldhuizen J.J., Kataoka O., Garber S.B., Kingsbury J.S., and Harrity J.P. Org. Biomol. Chem. 2 (2004) 8-23
39. Grubbs R.H. Tetrahedron 60 (2004) 7117-7140
40. Prunet J. Angew. Chem., Int. Ed. 42 (2003) 2826-2830
41. corrigendum. Prunet J. Angew. Chem., Int. Ed. 42 (2003) 3322
42. Gradillas A., and Pérez-Castells J. Angew. Chem., Int. Ed. 45 (2006) 6086-6101
43. Schwab P., France M.B., Ziller J.W., and Grubbs R.H. Angew. Chem., Int. Ed. 34 (1995) 2039-2041
44. 1H NMR and MS analyses indicated that the mixture contained several C-2 symmetric cyclic dimers including head-to-head and head-to tail ones.
45. Scholl M., Ding S., Lee C.W., and Grubbs R.H. Org. Lett. 1 (1999) 953-956
46. Synthesis of a similar compound has been reported. Hanessian S., Huang G., Chenel C., Machaalani R., and Loiseleur O. J. Org. Chem. 70 (2005) 6721-6734
47. Creighton C.J., and Reitz A.B. Org. Lett. 3 (2001) 893-895
48. Vo-Thanh G., Boucard V., Sauriat-Dorizon H., and Guibe F. Synlett 1 (2001) 37-40
49. One of the atropisomers was used. It was confirmed that the use of the other atropisomer also gave the similar results to afford trans-4.
50. Biological activity of cis- and trans-4 was briefly examined, however none of them showed cytotoxicity against human breast cancer SKBr-4 cells.